Company Announcement
- Median 22.4 month progression free survival in patients
treated with ofatumumab plus chlorambucil, an improvement of 9.3
months compared to chlorambucil alone
- No unexpected safety findings
Genmab A/S (Copenhagen:GEN) and
GlaxoSmithKline plc (GSK) announced today that their Phase III
study of ARZERRA(R) (ofatumumab) in combination with chlorambucil
versus chlorambucil alone in patients with previously untreated
chronic lymphocytic leukemia (CLL) met its primary endpoint of
progression free survival (PFS) as assessed by an Independent
Review Committee (IRC).
A total of 447 patients were enrolled in the study. A 9.3 month
improvement in the time a patient lived without worsening of their
disease (median PFS) was seen in patients randomized to ofatumumab
and chlorambucil compared to patients randomized to chlorambucil
alone (22.4 months vs. 13.1 months; Hazard Ratio 0.57; p=1%)
serious adverse events as reported by the investigator within 60
days of last treatment were neutropenia [including febrile
neutropenia] (5%), anaemia (4%), pneumonia (4%), and pyrexia (2%).
Infusion reactions were mild to moderate in severity with 3% of
infusion reactions reported as serious.
"We are delighted with the positive results from this trial
which we believe may lead to ofatumumab plus chlorambucil as an
additional treatment option for the care of patients with CLL,"
said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
"We look forward to submitting the study results, including
secondary endpoints, to the International Workshop on CLL (iwCLL)
in Cologne, Germany this September."
"As the aim of treating CLL, particularly in the frontline
setting, is to maximize progression free survival while minimizing
side effects, we are therefore encouraged by these promising
results," said Dr. Kathy Rouan, Vice President BioPharmaceutical
Development, GlaxoSmithKline. "We are planning regulatory
submissions in the EU, US, and other regions in the coming
months."
About the study
This Phase III study (NCT00748189) included patients with
previously untreated CLL considered inappropriate for
fludarabine-based therapy. Patients in the study were
randomized 1:1 to treatment with up to twelve cycles of ofatumumab
in combination with chlorambucil or up to twelve cycles of
chlorambucil alone. The primary endpoint of the study was PFS
according to the International Workshop for Chronic Lymphocytic
Leukaemia (IWCLL) updated 2008 National Cancer Institute-sponsored
Working Group (NCIWG) guidelines, using an independent endpoints
review committee.
About chronic lymphocytic leukemia
CLL is the most common form of leukemia in adults. Based on
estimates by the American Cancer Society, CLL will account for more
than 15,680 new cases and more than 4,580 deaths in the United
States of America alone in 2013. At present, no curative
chemotherapy is available.
About ARZERRA (ofatumumab)
Ofatumumab is not approved or licensed anywhere in the world for
use in patients who have not received treatment for
CLL. For Full US Prescribing Information, please visit:
http://us.gsk.com/html/medicines/index.html and visit
http://health.gsk.com/ for the EU SPC for the approved
indication.
Ofatumumab is a human monoclonal antibody which targets an
epitope on the CD20 molecule encompassing parts of the small and
large extracellular loops (Teeling et al 2006). Ofatumumab is being
developed under a co-development and commercialization agreement
between Genmab and GlaxoSmithKline.
About GSK
GSK is one of the world's leading research-based pharmaceutical
and healthcare companies - is committed to improving the quality of
human life by enabling people to do more, feel better, and live
longer. For further information please visit www.gsk.com.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company
specializing in the creation and development of differentiated
human antibody therapeutics for the treatment of cancer.
Founded in 1999, the company's first marketed antibody,
ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and
alemtuzumab after less than eight years in development.
Genmab's validated and next generation antibody technologies
are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company
has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com.
GSK Contact:
UK Media enquiries: David
Mawdsley
+44 (0) 20 8047 5502 (London) David
Daley
+44 (0) 20 8047 5502 (London) Catherine
Hartley
+44 (0) 20 8047 5502 (London) US Media enquiries: Bernadette
King +1
215 751 3632 (Philadelphia) Anna
Padula
+1 215 751 4271 (Philadelphia) Melinda
Stubbee
+1 919 483 2510 (North Carolina) Karen
Collins
+1 919 483 2527 (North Carolina) Stephen
Rea
+1 215 751 4394 (Philadelphia) Analyst/Investor enquiries: Ziba
Shamsi
+44 (0) 20 8047 3289 (London) Lucy
Budd
+44 (0) 20 8047 2248 (London) Tom
Curry
+1 215 751 5419 (Philadelphia) Gary
Davies
+44 (0) 20 8047 5503 (London) James
Dodwell
+44 (0) 20 8047 2406 (London) Jeff
McLaughlin
+1 215 751 7002 (Philadelphia)
Genmab Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor
Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62
60; E: r.gravesen@genmab.com
Cautionary Statement Regarding Forward
Looking-Statements for GSK
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Factors that may
affect GSK' s operations are described under Item 3.D 'Risk
factors' in the company's Annual Report on Form 20-F for 2012.
Forward Looking Statement for Genmab
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products obsolete, and other factors. For a further discussion of
these risks, please refer to the risk management sections in
Genmab's most recent financial reports, which are available on
www.genmab.com . Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement
nor to confirm such statements in relation to actual results,
unless required by law.
Genmab A/S and its subsidiaries own the following trademarks:
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R);
DuoBody(R), HexaBodyTM and UniBody(R). Arzerra(R) is a trademark of
GlaxoSmithKline.
Company Announcement no. 24 CVR no. 2102 3884
Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark